PROSPECT Trial Confirms Feasibility of De-escalation of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Michael Cecchini, MD, expands on key updates in gastrointestinal cancer from the 2023 ASCO Annual Meeting, including the clinical significance of findings from the PROSPECT and phase 3 PRODIGE 23 trials of perioperative chemotherapy vs selective standard chemoradiation.
New Haven United States Michael Cecchini Department Of Medical Oncology Yale Medicine Medical Oncology
Source: onclive.com